{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T18:16:18Z","timestamp":1789668978103,"version":"4.0.1"},"reference-count":28,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2016,2,12]],"date-time":"2016-02-12T00:00:00Z","timestamp":1455235200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2016,2,12]],"date-time":"2016-02-12T00:00:00Z","timestamp":1455235200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Blood Cancer Journal"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>The safety and efficacy of siltuximab (CNTO 328) was tested in combination with lenalidomide, bortezomib and dexamethasone (RVD) in patients with newly-diagnosed, previously untreated symptomatic multiple myeloma. Fourteen patients were enrolled in the study, eleven of whom qualified to receive therapy. A majority of patients (81.8%) completed the minimal number or more of the four required cycles, while two patients completed only three cycles. The maximum tolerated dose (MTD) of siltuximab with RVD was dose level \u22121 (siltuximab: 8.3\u2009mg\/kg; bortezomib: 1.3\u2009mg\/m<jats:sup>2<\/jats:sup>; lenalidomide: 25\u2009mg; dexamethasone: 20\u2009mg). Serious adverse events were grade 3 pneumonia and grade 4 thrombocytopenia, and no deaths occurred during the study or with follow-up (median follow-up 28.1 months). An overall response rate, after 3\u20134 cycles of therapy, of 90.9% (95% confidence interval (CI): 58.7%, 99.8%) (9.1% complete response (95% CI: 0.2%, 41.3%), 45.5% very good partial response (95% CI: 16.7%, 76.6%) and 36.4% partial response (95% CI: 10.9%, 69.2%)) was seen. Two patients withdrew consent, and nine patients (81.8%) opted for autologous stem cell transplantation.<\/jats:p>","DOI":"10.1038\/bcj.2016.4","type":"journal-article","created":{"date-parts":[[2016,2,12]],"date-time":"2016-02-12T09:20:46Z","timestamp":1455268846000},"page":"e396-e396","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":35,"title":["Siltuximab (CNTO 328) with lenalidomide, bortezomib and dexamethasone in newly-diagnosed, previously untreated multiple myeloma: an open-label phase I trial"],"prefix":"10.1038","volume":"6","author":[{"given":"J J","family":"Shah","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L","family":"Feng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S K","family":"Thomas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Z","family":"Berkova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D M","family":"Weber","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M H","family":"Qazilbash","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R E","family":"Champlin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T R","family":"Mendoza","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C","family":"Cleeland","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R Z","family":"Orlowski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2016,2,12]]},"reference":[{"key":"BFbcj20164_CR1","doi-asserted-by":"publisher","first-page":"9","DOI":"10.3322\/caac.21208","volume":"64","author":"R Siegel","year":"2014","unstructured":"Siegel R, Ma J, Zou Z, Jemal A . Cancer statistics, 2014. CA Cancer J Clin 2014; 64: 9\u201329.","journal-title":"CA Cancer J Clin"},{"key":"BFbcj20164_CR2","doi-asserted-by":"publisher","first-page":"2758","DOI":"10.1200\/JCO.2008.20.8983","volume":"27","author":"BD Smith","year":"2009","unstructured":"Smith BD, Smith GL, Hurria A, Hortobagyi GN, Buchholz TA . Future of cancer incidence in the United States: burdens upon an aging, changing nation. J Clin Oncol 2009; 27: 2758\u20132765.","journal-title":"J Clin Oncol"},{"key":"BFbcj20164_CR3","doi-asserted-by":"publisher","first-page":"181","DOI":"10.3816\/CLM.2005.n.045","volume":"6","author":"BG Durie","year":"2005","unstructured":"Durie BG . New approaches to treatment for multiple myeloma: durable remission and quality of life as primary goals. Clin Lymphoma Myeloma 2005; 6: 181\u2013190.","journal-title":"Clin Lymphoma Myeloma"},{"key":"BFbcj20164_CR4","doi-asserted-by":"publisher","first-page":"21","DOI":"10.4065\/78.1.21","volume":"78","author":"RA Kyle","year":"2003","unstructured":"Kyle RA, Gertz MA, Witzig TE, Lust JA, Lacy MQ, Dispenzieri et al. Review of 1027 patients with newly diagnosed multiple myeloma. Mayo Clin Proc 2003; 78: 21\u201333.","journal-title":"Mayo Clin Proc"},{"key":"BFbcj20164_CR5","doi-asserted-by":"publisher","first-page":"14374","DOI":"10.1073\/pnas.202445099","volume":"99","author":"N Mitsiades","year":"2002","unstructured":"Mitsiades N, Mitsiades CS, Poulaki V, Chauhan D, Fanourakis G, Gu X et al. Molecular sequelae of proteasome inhibition in human multiple myeloma cells. Proc Natl Acad Sci USA 2002; 99: 14374\u201314379.","journal-title":"Proc Natl Acad Sci USA"},{"key":"BFbcj20164_CR6","first-page":"3071","volume":"61","author":"T Hideshima","year":"2001","unstructured":"Hideshima T, Richardson P, Chauhan D, Palombella VJ, Elliott PJ, Adams J et al. The proteasome inhibitor PS-341 inhibits growth, induces apoptosis, and overcomes drug resistance in human multiple myeloma cells. Cancer Res 2001; 61: 3071\u20133076.","journal-title":"Cancer Res"},{"key":"BFbcj20164_CR7","doi-asserted-by":"publisher","first-page":"4525","DOI":"10.1182\/blood.V99.12.4525","volume":"99","author":"N Mitsiades","year":"2002","unstructured":"Mitsiades N, Mitsiades CS, Poulaki V, Chauhan D, Richardson PG, Hideshima T et al. Apoptotic signaling induced by immunomodulatory thalidomide analogs in human multiple myeloma cells: therapeutic implications. Blood 2002; 99: 4525\u20134530.","journal-title":"Blood"},{"key":"BFbcj20164_CR8","doi-asserted-by":"crossref","first-page":"8536","DOI":"10.1200\/jco.2009.27.15_suppl.8536","volume":"27","author":"KC Anderson","year":"2009","unstructured":"Anderson KC, Jagannath S, Jakubowiak A, Lonial S, Raje N, Alsina M et al. Lenalidomide, bortezomib, and dexamethasone in relapsed\/refractory multiple myeloma (MM): Encouraging outcomes and tolerability in a phase II study. J Clin Oncol 2009; 27: 8536.","journal-title":"J Clin Oncol"},{"key":"BFbcj20164_CR9","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1586\/ehm.10.83","volume":"4","author":"JP Laubach","year":"2011","unstructured":"Laubach JP, Schlossman RL, Mitsiades CS, Anderson KC, Richardson PG . Thalidomide Cenalidomide and bortezomib in the management of newly diagnosed multiple myeloma. Expert Rev Hematol 2011; 4: 51\u201360.","journal-title":"Expert Rev Hematol"},{"key":"BFbcj20164_CR10","doi-asserted-by":"publisher","first-page":"555","DOI":"10.3109\/10428194.2012.719614","volume":"54","author":"VH Jimenez-Zepeda","year":"2013","unstructured":"Jimenez-Zepeda VH, Reece DE, Trudel S, Chen C, Tiedemann R, Kukreti V . Lenalidomide (Revlimid), bortezomib (Velcade) and dexamethasone for heavily pretreated relapsed or refractory multiple myeloma. Leuk Lymphoma 2013; 54: 555\u2013560.","journal-title":"Leuk Lymphoma"},{"key":"BFbcj20164_CR11","doi-asserted-by":"crossref","first-page":"3880","DOI":"10.1182\/blood.V96.12.3880","volume":"96","author":"AC Rawstron","year":"2000","unstructured":"Rawstron AC, Fenton JA, Ashcroft J, English A, Jones RA, Richards SJ et al. The interleukin-6 receptor alpha-chain (CD126) is expressed by neoplastic but not normal plasma cells. Blood 2000; 96: 3880\u20133886.","journal-title":"Blood"},{"key":"BFbcj20164_CR12","doi-asserted-by":"publisher","first-page":"258","DOI":"10.1002\/ajh.2830310408","volume":"31","author":"O Tanabe","year":"1989","unstructured":"Tanabe O, Kawano M, Tanaka H, Iwato K, Asaoku H, Ishikawa H et al. BSF-2\/IL-6 does not augment Ig secretion but stimulates proliferation in myeloma cells. Am J Hematol 1989; 31: 258\u2013262.","journal-title":"Am J Hematol"},{"key":"BFbcj20164_CR13","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1182\/blood.V85.3.765.bloodjournal853765","volume":"85","author":"TT Pelliniemi","year":"1995","unstructured":"Pelliniemi TT, Irjala K, Mattila K, Pulkki K, Rajamaki A, Tienhaara et al. Immunoreactive interleukin-6 and acute phase proteins as prognostic factors in multiple myeloma. Finnish Leukemia Group. Blood 1995; 85: 765\u2013771.","journal-title":"Blood"},{"key":"BFbcj20164_CR14","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1182\/blood.V86.2.685.bloodjournal862685","volume":"86","author":"R Bataille","year":"1995","unstructured":"Bataille R, Barlogie B, Lu ZY, Rossi JF, Lavabre-Bertrand T, Beck T et al. Biologic effects of anti-interleukin-6 murine monoclonal antibody in advanced multiple myeloma. Blood 1995; 86: 685\u2013691.","journal-title":"Blood"},{"key":"BFbcj20164_CR15","doi-asserted-by":"publisher","first-page":"248","DOI":"10.1006\/cimm.1995.1076","volume":"162","author":"A Lichtenstein","year":"1995","unstructured":"Lichtenstein A, Tu Y, Fady C, Vescio R, Berenson J . Interleukin-6 inhibits apoptosis of malignant plasma cells. Cell Immunol 1995; 162: 248\u2013255.","journal-title":"Cell Immunol"},{"key":"BFbcj20164_CR16","doi-asserted-by":"crossref","first-page":"3063","DOI":"10.1182\/blood.V84.9.3063.3063","volume":"84","author":"J Hardin","year":"1994","unstructured":"Hardin J, MacLeod S, Grigorieva I, Chang R, Barlogie B, Xiao H et al. Interleukin-6 prevents dexamethasone-induced myeloma cell death. Blood 1994; 84: 3063\u20133070.","journal-title":"Blood"},{"key":"BFbcj20164_CR17","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1182\/blood.V89.1.227","volume":"89","author":"D Chauhan","year":"1997","unstructured":"Chauhan D, Kharbanda S, Ogata A, Urashima M, Teoh G, Robertson M et al. Interleukin-6 inhibits Fas-induced apoptosis and stress-activated protein kinase activation in multiple myeloma cells. Blood 1997; 89: 227\u2013234.","journal-title":"Blood"},{"key":"BFbcj20164_CR18","doi-asserted-by":"publisher","first-page":"1248","DOI":"10.1158\/1078-0432.CCR-14-2291","volume":"21","author":"JF Rossi","year":"2015","unstructured":"Rossi JF, Lu ZY, Jourdan M, Klein B . Interleukin-6 as a therapeutic target. Clin Cancer Res 2015; 21: 1248\u20131257.","journal-title":"Clin Cancer Res"},{"key":"BFbcj20164_CR19","doi-asserted-by":"publisher","first-page":"379","DOI":"10.1038\/sj.thj.6200312","volume":"4","author":"BG Durie","year":"2003","unstructured":"Durie BG, Kyle RA, Belch A, Bensinger W, Blade J, Boccadoro M et al. Myeloma management guidelines: a consensus report from the Scientific Advisors of the International Myeloma Foundation. Hematol J 2003; 4: 379\u2013398.","journal-title":"Hematol J"},{"key":"BFbcj20164_CR20","doi-asserted-by":"publisher","first-page":"925","DOI":"10.2307\/2531693","volume":"45","author":"BE Storer","year":"1989","unstructured":"Storer BE . Design and analysis of phase I clinical trials. Biometrics 1989; 45: 925\u2013937.","journal-title":"Biometrics"},{"key":"BFbcj20164_CR21","doi-asserted-by":"publisher","first-page":"1115","DOI":"10.1046\/j.1365-2141.1998.00930.x","volume":"102","author":"J Blade","year":"1998","unstructured":"Blade J, Samson D, Reece D, Apperley J, Bjorkstrand B, Gahrton G et al. Criteria for evaluating disease response and progression in patients with multiple myeloma treated by high-dose therapy and haemopoietic stem cell transplantation. Myeloma Subcommittee of the EBMT. European Group for Blood and Marrow Transplant. Br J Haematol 1998; 102: 1115\u20131123.","journal-title":"Br J Haematol"},{"key":"BFbcj20164_CR22","doi-asserted-by":"publisher","first-page":"e538","DOI":"10.1016\/S1470-2045(14)70442-5","volume":"15","author":"SV Rajkumar","year":"2014","unstructured":"Rajkumar SV, Dimopoulos MA, Palumbo A, Blade J, Merlini G, Mateos MV et al. International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma. Lancet Oncol 2014; 15: e538\u2013e548.","journal-title":"Lancet Oncol"},{"key":"BFbcj20164_CR23","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1186\/1756-8722-6-13","volume":"6","author":"D Jones","year":"2013","unstructured":"Jones D, Vichaya EG, Wang XS, Williams LA, Shah ND, Thomas SK et al. Validation of the M. D. Anderson Symptom Inventory multiple myeloma module. J Hematol Oncol 2013; 6: 13.","journal-title":"J Hematol Oncol"},{"key":"BFbcj20164_CR24","doi-asserted-by":"publisher","first-page":"3659","DOI":"10.1158\/1078-0432.CCR-12-3349","volume":"19","author":"R Kurzrock","year":"2013","unstructured":"Kurzrock R, Voorhees PM, Casper C, Furman RR, Fayad L, Lonial S et al. A phase I, open-label study of siltuximab, an anti-IL-6 monoclonal antibody, in patients with B-cell non-Hodgkin lymphoma, multiple myeloma, or Castleman disease. Clin Cancer Res 2013; 19: 3659\u20133670.","journal-title":"Clin Cancer Res"},{"key":"BFbcj20164_CR25","doi-asserted-by":"publisher","first-page":"357","DOI":"10.1111\/bjh.12266","volume":"161","author":"PM Voorhees","year":"2013","unstructured":"Voorhees PM, Manges RF, Sonneveld P, Jagannath S, Somlo G, Krishnan et al. A phase 2 multicentre study of siltuximab, an anti-interleukin-6 monoclonal antibody, in patients with relapsed or refractory multiple myeloma. Br J Haematol 2013; 161: 357\u2013366.","journal-title":"Br J Haematol"},{"key":"BFbcj20164_CR26","doi-asserted-by":"publisher","first-page":"4136","DOI":"10.1182\/blood-2013-12-546374","volume":"123","author":"J San-Miguel","year":"2014","unstructured":"San-Miguel J, Blade J, Shpilberg O, Grosicki S, Maloisel F, Min CK et al. Phase 2 randomized study of bortezomib-melphalan-prednisone with or without siltuximab (anti-IL-6) in multiple myeloma. Blood 2014; 123: 4136\u20134142.","journal-title":"Blood"},{"key":"BFbcj20164_CR27","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1002\/ajh.23868","volume":"90","author":"RZ Orlowski","year":"2015","unstructured":"Orlowski RZ, Gercheva L, Williams C, Sutherland H, Robak T, Masszi T et al. A phase 2, randomized, double-blind, placebo-controlled study of siltuximab (anti-IL-6 mAb) and bortezomib versus bortezomib alone in patients with relapsed or refractory multiple myeloma. Am J Hematol 2015; 90: 42\u201349.","journal-title":"Am J Hematol"},{"key":"BFbcj20164_CR28","doi-asserted-by":"publisher","first-page":"679","DOI":"10.1182\/blood-2010-02-268862","volume":"116","author":"PG Richardson","year":"2010","unstructured":"Richardson PG, Weller E, Lonial S, Jakubowiak AJ, Jagannath S, Raje NS et al. Lenalidomide, bortezomib, and dexamethasone combination therapy in patients with newly diagnosed multiple myeloma. Blood 2010; 116: 679\u2013686.","journal-title":"Blood"}],"container-title":["Blood Cancer Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/bcj20164.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/bcj20164","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/bcj20164.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,1,4]],"date-time":"2023-01-04T04:05:29Z","timestamp":1672805129000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/bcj20164"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,2,12]]},"references-count":28,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2016,2]]}},"alternative-id":["BFbcj20164"],"URL":"https:\/\/doi.org\/10.1038\/bcj.2016.4","relation":{},"ISSN":["2044-5385"],"issn-type":[{"value":"2044-5385","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,2,12]]},"assertion":[{"value":"17 November 2015","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 January 2016","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 February 2016","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"This study was funded by Johnson & Johnson. JJS has received research funding from Array, Celgene, Millennium\/Takeda, Novartis, and Onyx\/Amgen. SKT has received research funding from Acerta Pharma, Celgene, Idera Pharmaceuticals, Millenium\/Takeda, and Novartis. MW has received research funding from Celgene and Millennium\/Takeda. RZO has served on advisory boards for and has research funding support from Celgene and Onyx\/Amgen.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}